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Influence of health technology assessment and its measurement 
Abstract 
OBJECTIVES: The aim of this study was to obtain information on methods used to measure health 
technology assessment (HTA) influence, decisions that were influenced, and outcomes linked to HTA. 
METHODS: Electronic databases were used to locate studies in which HTA influence had been 
demonstrated. Inclusion criteria were studies that reliably reported consideration by decision makers of 
HTA findings; comparative studies of technology use before and after HTA; and details of changes in 
policy, health outcomes, or research that could be credibly linked to an HTA. RESULTS: Fifty-one studies 
were selected for review. Settings were national (24), regional (12), both national and regional (3) 
hospitals (9), and multinational (3). The most common approach to appraisal of influence was review of 
policy or administrative decisions following HTA recommendations (51 percent). Eighteen studies (35 
percent) reported interview or survey findings, thirteen (26 percent) reviewed administrative data, and six 
considered the influence of primary studies. Of 142 decisions informed by HTA, the most common types 
were on routine clinical practice (67 percent of studies), coverage (63 percent), and program operation (37 
percent). The most frequent indications of HTA influence were on decisions related to resource allocation 
(59 percent), change in practice pattern (31 percent), and incorporation of HTA details in reference 
material (18 percent). Few publications assessed the contribution of HTA to changing patient outcomes. 
CONCLUSIONS: The literature on HTA influence remains limited, with little on longer term effects on 
practice and outcomes. The reviewed publications indicated how HTA is being used in different settings 
and approaches to measuring its influence that might be more widely applied, such as surveys and 
monitoring administrative data. 
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Objectives:  To obtain information on methods used to measure HTA influence, decisions that were influenced, and outcomes linked to HTA. 
Methods: Electronic data bases were used to locate studies in which HTA influence had been demonstrated. Inclusion criteria were studies 
that reliably reported consideration by decision-makers of HTA findings; comparative studies of technology use before and after HTA; and 
details of changes in policy, health outcomes or research that could be credibly linked to an HTA. 
Results:  51 studies were selected for review. Settings were national (24), regional (12), both national and regional (3), hospitals (9) and 
multinational (3). The most common approach to appraisal of influence was review of policy or administrative decisions following HTA 
recommendations (51%). Eighteen studies (35%) reported interview or survey findings, 13 (26%) reviewed administrative data and six 
considered the influence of primary studies.  Of 142 decisions informed by HTA the most common types were on routine clinical practice (67% 
of studies), coverage (63%), and program operation (37%).  Most frequent indications of HTA influence were on decisions related to resource 
allocation (59%) change in practice pattern (31%) and incorporation of HTA details in reference material (18%).  Few publications assessed the 
contribution of HTA to changing patient outcomes. 
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Conclusions:  The literature on HTA influence remains limited, with little on longer term effects on practice and outcomes.  The reviewed 
publications indicated how HTA is being used in different settings and approaches to measuring its influence that might be more widely 
applied, such as surveys and monitoring administrative data.  
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Health technology assessment is used to inform decisions relating to health care systems.  The effectiveness of an HTA program will depend on 
its influence - the extent to which information provided in its publications has had an effect on decision makers and in what ways.  In this 
paper, HTA influence is considered to be any action or activity that can be credibly linked to information provided to a decision maker by an 
assessment [1].  HTA influence is used rather than “HTA impact”, as representing a more realistic indication of the place of HTA in decision- 
making. 
 Information on the influence of HTA reports is a guide to the effectiveness of an assessment program.  Such information is useful in reporting 
to funders of HTA programs, in quality assurance processes, and in contributing to global indications of HTA achievements.  In principle, there 
will be interest in the influence of HTA on policy and administrative decisions, subsequent administrative action, delivery of health care and on 
health status [1].    Much of the focus on HTA influence has been on the first of these. Subsequent administrative action is dependent on the 
availability of effective machinery and the willingness of the decision maker to make use of it. Influence of an HTA report on subsequent action 




There is still relatively little information available on the influence of HTA on health care decisions and their outcomes.  Also, there is limited 
detail available on methods used to assess HTA influence and the experience of HTA programs in applying such approaches.  A review by 
Gerhardus and Dintsios concluded there was little experience with study designs or methods that allow a valid assessment of the impact of 
HTA reports on the decision making process.  Only limited conclusions related to the impact of HTA reports could be drawn [2]. 
A review of policies and processes for the introduction of new interventional procedures into clinical practice identified seven studies that 
described outcomes of policies [3]. The results showed that while the safety, efficacy and clinical and cost-effectiveness of new health 
technologies are important considerations in the decision-making process, a number of other factors also play an important role.  Decisions 
were never based solely on the findings of HTAs.  Niessen et al. [4] reported that 30 studies, including some on HTAs, found that use of 
economic evidence had a “substantial” impact on health care policy making; 27 studies emphasized at least one other criterion.  A further 11 
studies found only a limited impact and two studies showed no impact. 
The International Network of Agencies for Health Technology Assessment (INAHTA) had obtained information on HTA influence from its 
members but had not reviewed the available literature. The network decided in 2012 that a working group would undertake a systematic 
review of reports on HTA influence and its measurement. Five groups of either two or three reviewers were formed by working group 
members to share the tasks of abstract selection and data extraction.  The Swedish Council on Technology Assessment in Health Care (SBU) 
undertook the literature review and provided project support.   
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A report on the review is available on the INAHTA website [5].  For this article on the review, the literature search was updated and additional 
publications included. Further details were provided on the derivation of the categories used in reporting the review findings, and an 
additional presentation linking details of technologies that were assessed with indicators of HTA influence.   Material in the tables was updated 
to reflect data from the additional studies and include percentages.  
The objectives of the systematic review were to obtain information on the influence of HTAs on health care decisions and their outcomes, and 
on the methods used to measure such influence.  
METHODS  
A protocol for the review was prepared by members of the working group. Broad inclusion criteria were specified covering studies reporting 
consideration of HTA findings, and changes in policy, health technology use, health outcomes, or increased level of research. 
Published literature was identified using PubMed, Embase, Cinahl , Cochrane Library, PsychInfo, NHSeed, HTA database, DARE, NHS Evidence, 
and the Swedish HTA database.  The searches were supplemented by hand searching the bibliographies of selected papers and through 
contacts with HTA and other agencies. Publication dates were 2000 – August 2014, subsequently extended to November 2015. There were no 
language restrictions.  Search terms included Technology Assessment, Biomedical, HTA, systematic review, evidence-informed, impact, 
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influence, information dissemination, implement, policy making, health policy and decision making. Further details of the literature search 
strategy are available in the INAHTA report on the project [5].   
 Inclusion criteria were studies that reliably reported consideration by decision-makers of HTA findings and/or recommendations; comparative 
studies that included relevant measures related to use of a health technology before and after dissemination of an HTA; and studies that 
reported changes in one or more features that could be credibly linked to information provided by an HTA. Those features were policy related 
to a health technology, use of a health technology in a health care system, relevant health outcomes associated with use of a health 
technology, and an increased level of research or initiation of research. Expert opinion, correspondence, commentaries and duplicate 
publications on the same study were excluded. 
A data extraction form was developed, which included lists on approaches to assessing influence, types of decision, indications of HTA 
influence and opinions on influence used in previous INAHTA publications [1, 6].  The form also included five indicators of study quality that 
were specified in the protocol.  These had some relevance to quality but were also related to the scope of a study (Supplementary List 1). 
Quality ratings were given by the number of indicators that applied to each study, with scores from 1 to 5. 
Each reviewer group was allocated a list of identified publications for initial screening using titles, abstracts and keywords. Any citations 
considered relevant or for which there was uncertainty were retained at that stage and the full papers obtained. The identified publications 
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were considered independently by the reviewer groups and selected if they met the inclusion criteria. Differences between individuals within 
the reviewer groups were discussed and resolved by consensus. 
Information extracted from the selected publications by the reviewer groups included the study setting, health technologies that were 
assessed, types of decision informed by the assessment, the approach used to assess HTA influence, main indications of influence, measures 
and/or opinion on influence, and non-HTA influences on outcomes. Any disagreements were resolved through discussion. For publications 
covering many HTA reports, the technologies were listed but other elements in the data extraction were based on the summary information 
that was provided, rather than considering each recommendation and its influence individually.  
In some cases, the authors’ opinion on level of HTA influence was reported, or was apparent from details presented in the reviewed 
publication. For other publications, a judgement on the level of influence was made by the reviewers.  Level of influence was recorded on a 
four point scale used in previous INAHTA projects (major influence on decisions, some input to decisions, some consideration of the 
assessment, minimal influence) [6].  
RESULTS 
After removal of duplicates, 4,767 publications were identified by the literature search. An overview of publication selection is shown in 
Supplementary Figure 1. Adjustments to initial selections were made through exclusion of earlier publications from series of reports on the 
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same topic, papers that were not related to influence of HTA, and publications where there was insufficient information to provide a clear 
indication of influence.  Fifty five publications covering 51 studies were selected for review.  Reports on measurement of HTA influence were 
obtained from 19 countries – Argentina, Australia, Austria, Belgium, Canada, France, Finland, Germany, Italy, Malaysia, the Netherlands, the 
PRC, Poland, Spain, Sweden, Switzerland, Thailand, the UK and the USA.  Three publications provided information on more than one country - 
a report on EU countries, a survey with details from Australia, Brazil, Canada, Spain and the USA, and a survey of Latin American and Caribbean 
countries. Study settings were national (24), regional (12), both national and regional (3), multinational (3), and hospitals (9).  
Approaches taken to appraisal of HTA influence are shown in Table 1.  Several studies used more than one approach. The most common was 
review of policy, and of acceptance of HTA recommendations (in 51% of studies).   Eighteen studies (36%) used surveys or interviews with 
decision makers, 13 (26%) reviewed or analysed administrative data, and six (12%) considered the influence of primary studies.  
Types of decisions informed by the HTAs are shown in Table 2. Decisions related to routine practice (in 67% of studies), coverage (63%), 
program operation (37%) and capital funding (35%) were the most common categories.  Table 3 shows the indications of HTA influence that 
were noted during data extraction.  Several studies showed more than one influence on decisions. Influence on decisions involving resource 
allocation was the most frequent indication (in 59% of studies).  There were also a number of indications related to effects on practice (31%), 
and incorporation of HTA details into reference material such as guidelines and program management manuals (18%). 
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Opinion from 21 (41%) of the studies was that HTA had had a major influence on decisions.  In 13 studies (25%) HTA had provided some input 
to decisions, with 6 (12%) there was some consideration of the assessment and in 3 studies there was minimal influence.   In the other 8 
studies, details given indicated that HTA influence on decisions had varied for different technologies (major influence 80 (54%), input to 
decisions 24 (16%), consideration of the assessment 36 (24%), minimal 9 (6%)). Some of the ‘minimal’ ratings were associated with the early 
stages of HTA programs. Quality ratings were high (5 or 4) for 27 studies (53%).  Seventeen (33%) had a rating of 3 and seven a rating of 2.  
Brief details of material in the reviewed publications are shown in Table 4. Assessments on medical devices and surgical procedures informed 
decisions on coverage and conditions of use for technologies, with consequences for routine practice.  The studies on screening technology 
point to the importance of HTA in providing input to government processes for  the development and implementation of national screening 
programs.  HTAs had a major influence on coverage decisions for pharmaceuticals; there were limitations in the influence of negative 
recommendations on the use of some drugs.  The studies also indicated the place and value of rapid assessments and the success of hospital 
HTA programs in influencing local policy and administrative decisions. Further information is presented in Supplementary Tables 1 and 2. 
DISCUSSION 
Both positive and negative HTA findings on health technologies were influential. Many related to relatively short- term targets (policy and 
administrative decisions). Some also covered subsequent administrative action and program planning issues.  Gerhardus and Dintsios [2] refer 
to use of interviews with decision-makers, document analysis, surveys and use of administrative data as methods in the evaluation of HTA 
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influence.  A similar mix of approaches was used by the studies included in this review, and also appraisal of the effects of primary studies. 
Approaches using review of decisions seemed useful. Some HTA programs had close contact with decision makers, giving opportunities for 
realistic appraisals.  
The reviewed studies provide good examples of the place of HTA in health care decision-making. Information on the influence of assessments 
can have a role in making a contribution to a broader, global perspective of HTA’s achievements and usefulness [1].  There were clear 
indications of the benefits to both decision-makers and HTA researchers from maintaining regular, appropriate contact at all stages of the HTA 
process (Supplementary Tables 1 and 2). For decision-makers there are examples of the sorts of decisions and programs that HTA informs.  
There are some insights into the decision making process, and indications of savings, efficiencies and practice changes linked to HTA findings.  
There are lessons to be learned from some limitations, both in consideration of HTA advice and in the implementation of decisions. 
There were also examples that might be followed more widely on approaches to measuring influences.  Valuable information on some longer 
term influences was obtained through monitoring administrative data and through survey approaches. Primary studies can form a useful part 
of the HTA process, as shown through indications of changes to practice patterns, relating to the delivery of health care [1]. 
 There was little indication of influence of HTA on the health status of patients, though this was captured to some extent by a review of SBU 
assessments.   Two studies reported use of HTA linked to coverage with evidence development (CED) for consideration of policy decisions at 
regional or national level. A CED approach was also used with an HTA program that evaluated surgical technologies. Estimates of savings 
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achieved through use of HTA were found in studies covering hospitals in Montréal and Buenos Aires, and in a study of HTA in Austria which 
noted contributions to disinvestment decisions.  
The literature covering the matters addressed by this review is still quite limited. Few recent studies have considered the influence of HTA in 
any detail, and there is little on the longer term effects on clinical practice and health outcomes.   
There is a progression of possible influence, from the decision maker level with increased knowledge and awareness, to changes in policy and 
healthcare delivery, up to changes in patient outcomes. Changes to health care and improved health are dependent on the actions of many 
individuals and organizations. Measuring change across all stages of influence should be considered, as the contribution of the HTA to changes 
in patient outcomes is not going to occur if these earlier stages of influence have not first been realised.  
Detailed appraisal of HTA influence, especially in the longer term, can become a significant research project. Such projects may be resource 
intensive, and be undertaken only occasionally.   Availability of data may be an issue; access to records may need to be negotiated, or surveys 
of users of health technologies put in place.  However, shorter - term evaluation of influence on decision makers may need only modest 
resources. Essentially it is a question of incorporating approaches to obtaining indications of influence into the routine management of an HTA 
program [1].   
Both assessors and decision makers have important roles and responsibilities in the HTA process.   Future studies on HTA influence will be 
facilitated by good and continuing interaction between these parties. The HTA agency should aim to generate some reaction from decision 
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makers to the material and advice that have been provided.  There should be contact with the decision makers early in the assessment process 
and while the project is in progress. It is necessary to maintain a dialogue [62]. 
A monitoring system developed in Québec used telephone interviews with requesters and users to obtain reactions of decision makers to HTA 
reports and intended action on the technologies that had been assessed [1]. Perceived relevance of recommendations and intention to adopt 
recommendations can be used as a proxy for influence [62]. The INAHTA impact framework provides a basic approach to collecting 
information on HTA influence [6].  Approaches based in part on application of the framework have been able to capture details of at least short 
term influence [41]. Resources for more detailed studies on longer term influence of HTA should preferably be a matter for negotiation 
between the assessment agency, its governance and decision makers at an early stage.  
Further studies would also be facilitated by encouragement for agencies and their clients to give details of both successes and failures of their 
HTAs in influencing decisions.  ‘Failures’ as well as successes need to be considered and acted on if influence measurement is to be useful for 
HTA program management, and as feedback to clients.   Open provision and wide distribution by HTA programs of information on their 
influence has been recommended [1].  
This systematic review had several limitations.  The estimated extent of influence is based on the authors’ findings and opinions, or on our to 
some extent subjective judgements, and should be critically reviewed. We may expect some degree of publication bias towards positive 
stories, but it is difficult to assess the extent of this. There were restrictions on the dates and scope of the literature search and on the 
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approach taken to assessment of study quality, to take account of time and resources available to reviewers. On the other hand, the quality 
appraisal approach that was used touched on some things that are often not considered in a formal fashion.  The information presented is 
largely confined to summaries of details in the selected publications. There was not sufficient time to scan and follow up reference lists of 
included publications or to carry out citation searching.  For example, an overview by Raftery and Powell of the UK Health Technology 
Assessment programme gives some indications of HTA influence that could be followed up [63].   Nor was it possible to systematically search 
the grey literature for evaluations of HTA programs and their influence. 
POLICY IMPLICATIONS 
While there is variation in the influence that HTA reports or programs might have, most of the examples considered here informed decisions 
on health technologies. All but three of the 51 studies identified successful HTA influence. HTA has been an important input to policy 
formulation and implementation in many settings.  The publications covered by this review have much useful information related to HTA 
influence including approaches that might be used more often.  Some of them had been produced as components of HTA program 
management [1]. 
The limited number of studies following change in clinical practice and health outcomes indicates that these areas need much more attention 
in the future. Quality registers and clinical data bases are growing rapidly around the world and they could be very useful tools for analysing 
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Table 1: Approaches taken in assessing HTA influence * 
 Number of studies % 
Review of policy, and of acceptance of HTA recommendations 
[10,12,14,18,21-24,26,28-32,36,38,39,41-46,48,50,51,57,60]   
26 51 
Questionnaire surveys of decision makers or agencies 
[20,34,35,47,55,57,58,60,61] 
8 16 
Qualitative interviews with decision makers 
[16,33-35,37,38,40,43,45,58] 
8 16 
Analysis of administrative data  
[7,9,18,37,52,53,60] 
7 14 
Review of policy and of administrative data 
[13,15,17,19,49,58] 
6 12 
Review of the effects of primary studies 
[8,27,56-59] 
6 12 









Table 2: Types of decisions informed by HTA  
Types of decision * Number of studies % 












Guideline formulation   
[7,8,11,13,14,29,34,35,40-42,55,57-61] 
14 27 
Indications for further research 
[12,17,38,43,45,47,48,55,57,58,60,61] 
12 24 







Other a  3 6 
a) Other decisions: Equipment sales [19], Legislation to regulate program [23], Strategy planning process [34, 35] 
Table 3: Indications of HTA influence 
Indication * Number of studies % 
Acceptance of recommendations, linked to resource allocation 
[7,9-11,13-17,21-25,28,30,32,36,37,39-43,45-51,54]  
30 59 
Change in practice pattern   
[8, 12,13,15,17-20,33,37,52,53,56-58,60] 
16 31 
Incorporation of HTA details in reference material  
[29,34,35,40-42,47,55,58-60] 
9 18 




Influence on research  
[12,17,44,60] 
4 8 
Acceptance of recommendations, clinical indications  
[44,48,58] 
3 6 
Influence on other HTA programs [58,61] 2 4 





Table 4: Details of technologies and HTA influence  
Area Topic Indicators of HTA influence 
Medical devices Drug-eluting stents * Available only for high-risk patients with abdominal aortic 
aneurysm [7] 
 Peritoneal drainage catheter *Availability for persons with recurrent malignant ascites [11] 
 Robotic surgery *Agreement on indications and criteria for treatment [12] 
 Cochlear implantation *Agreement on criteria for treatment [14]  Decision not to 
support bilateral CI for children [15] 
 Surgical devices *Use by a purchasing organization for procurement decisions 
[27] 
Diagnostic services Preoperative examinations * Reduction in use of these services [19] 
 Pediatric radiology * Effects of guidelines on practice patterns [8] 
 Pharmacogenomics in treatment of H. 
pylori infection 
* Determination that the technology was investigational  [28] 
Screening 
technologies 
Breast cancer  Acceptance of HTAs  by governments, introduction of national 
programs [17,18]   
32 
 
 Prostate cancer  * Recommendations against screening accepted, influence on 
practice patterns limited by opportunistic testing  [17,18] 
 Maternal screening in pregnancy * Acceptance of HTAs  by governments,  introduction of 
national programs [18,21,23] and a Ministry guideline [29] 
 Newborn screening * Introduction and expansion of screening programs [30, 31].  
* Coverage processes better when associated with HTA  [22] 
 Abdominal aortic aneurysm screening * Service funded following HTA [26] 
   
 
Surgical and other 
procedures 
Disc arthroplasty  * Contributed to a decision on coverage following CED [9] 
 Hand transplantation  * Decision not to fund  procedure [10] 
 Cardiac bypass surgery  * Expansion of open heart surgery services  [24] 




 Prioritization procedures  * Decisions for cataract surgery, joint replacement [25]  
bariatric surgery [26] 
  
Respiratory disease  Approaches to management  * Changes in health services and  clinical practice [33] 
Public health Tobacco prevention  * HTA program influenced dental professionals [20] 
 Planning for facilities and services  * HTAs influenced public health- related decisions [34,35] 
National HTA 
programs 
Coverage and other decisions, guidelines 
and clinical practice 
 * Acceptance of advice on coverage, disinvestment, guidelines 
and practice patterns, influence on policy [36-38,46, 56-60] 
 Pharmaceutical coverage and use  * Major influence on coverage decisions [49-51] 
* Changes in the level of use for management of blood 
pressure, dyspepsia, multiple sclerosis [19] Negative appraisals  




Policy decisions based upon CED studies.   
Influence on ministry decisions 
 * Decisions consistent with HTA recommendations [39] 
* Most HTAs influenced policy or program decisions [41,42] 
34 
 
HTAs accepted by stakeholders [47]       





 *Informed decisions on surgical technologies [44],  new 
technologies [45, 48],  management of pediatric patients [13] 
Other topics Use of rapid HTAs  
 
* Health ministry decisions were consistent with HTA advice 
[54].   All HTAs had some influence [55].   
 
 Use of HTAs by other jurisdictions  *  HTAs from other jurisdictions used to guide decisions [61] 
 
 
Supplementary Figure 1 
Selection of publications 
 
 
Records from search 
screened after duplicates 
removed 
(n = 4,767) 
Records excluded 
(n =4,548) 
Records identified from 
other sources, (n=5) 
  
Publications included in 
review  
(n = 55 on 51 studies) 
Full-text articles assessed 
for eligibility 
(n = 219) 
Records excluded 
(n=169) 





* Earlier reports on 






Supplementary List 1:  Indications of study quality 
 
Answer the following questions (Yes/No) for each publication selected for review.  Score 
one point for each Yes answer and record the total score (maximum of 5). Higher scores 
tend to indicate that greater confidence can be placed in the quality and applicability of the 
study findings. 
* Were the findings of the HTA report(s) summarized? 
* Was the decision - making process that was influenced by the HTA described or 
referenced?  
* Was the approach used to assess HTA influence described?  
* Were outcomes or influence reported? 
* Were non – HTA influences considered? 
  
Abbreviations used in Supplementary Tables 1 and 2 
 
AAA: Abdominal aortic aneurysm 
ACE: Angiotensin-converting enzyme 
BCBS: Blue Cross and Blue Shield 
BDa: Bone density measurement 
CI: Cochlear implantation 
CED: Coverage with evidence development 
COPD: Chronic obstructive pulmonary disease 
EU: European Community 
HSR: Health services research 
ICER: Incremental cost-effectiveness ratio 
ICU: Intensive care unit 
NHS: National Health Service 
NICE: National Institute for Health and Care Excellence 
OCT: Optical coherence tomography 
PCR: Polymerase chain reaction 
PPI: Proton - pump inhibitor 
PSA: Prostate serum antigen 
vALY: vuality–adjusted life year 
SBU: Swedish Council on Technology Assessment in Health Care 
SaS: Scottish aedicines Consortium 
US: Ultrasound 
Xpert aTB/RIF: aycobacterium tuberculosis and rifampicin resistance test 
 
Supplementary Table 1.   Publications covering HTAs and small numbers of technologies 
Author, 
Technology 
Country/setting Types of 
decision 














Data on introduction and use 
following HTA & decision maker 
action 
Acceptance of recommendations 
re availability only for high-risk 











Sub analysis of prospective cohort 
study, aonte-Carlo simulation 
Guidelines do not increase 
workload, but move patient 
management from the 
observation ward to the radiology 
department 











Details of registry information 
following decision to use CED 
Coverage provided by insurance 
program 
aajor 5 









Details of a recommendation from 
an appraisal of the HTA report and 
subsequent consideration by the 
national accident insurance 
committee’ 
Decision not to fund hand 
transplantation for 
ethical reasons, because of 
considerable side effects, 
and relatively limited health gains, 
particularly for unilateral 
amputees 
aajor 4 





England, NHS  Referral, 
Guideline 
Formal decision process linked to 
HTA findings 
Acceptance of recommendation in 





Supplementary Table 1 (continued) 
Author, 
Technology 
Country/setting Types of 
decision 



















Review of decisions  following 
evaluation by multidisciplinary 
panel that included systematic 
review, analysis of local 
context, and identification 
of indications with promising 
clinical return. 
 
Agreement on clinical indications for which the 
robot should not be used and suspension of 
these by hospitals and surgeons. 
Agreement on a list of promising clinical 
indications and for evaluation locally  
Proposal by local surgeons, for two multicentre 
clinical trials  
 
aajor  3 
Demirdjian  













aonitoring decisions taken by 
hospital administrators. 
Review of administrative data 
Acceptance of recommendations on: 
* albumin solutions -  albumin consumption 
and associated costs reduced by 50% 
* cochlear implantation - 
a suitable device substituted 
for one with unacceptable performance 
* OCT - equipment was not incorporated 
* palivizumab – use in high risk patients 
* PCR – use in high risk patients 
Not accepted on: 
* reiki techniques (continued use in pre-
operative setting) 


















Advice re acceptance of 
recommendations following 
systematic review on clinical & 
economic aspects of CI 
Recommendations on criteria for treatment of 
several patient groups were approved with 
minimal suggestions by members of a 






Supplementary Table 1 (continued) 
Author, 
Technology 
Country/setting Types of 
decision 















Review of decisions by the 
ainistry of Health following 
systematic review on clinical 
aspects of bilateral CI, and 
analysis of administrative data 
on hearing services in 
Kazakhstan. 
ainistry of Health decided not to support 
provision of bilateral CI for deaf children. 
Action would be taken to procure 
equipment for early detection of children with  
hearing loss, and to strengthen rehabilitation 




















Interviews with stakeholders 
and experts, review of policy 
Use of technologies did not follow advice from 
available assessments. Lack of a systematic 




















Appraisal of program 
implementation, data on use 
of screening tests 
a) aammography – CEA was followed by 
national screening program for breast cancer 
b) Recommended against prostate cancer 
screening –, accepted by government but   
“quite a lot” of opportunistic screening.  
Recommendation re future research accepted 
by ministry & implemented 
c) Selective use supported, for high risk groups.  
But 80 -90% pregnancies screened with US 
 




Supplementary Table 1 (continued) 
Author, 
Technology 
Country/setting Types of 
decision 




Jonsson [18], 2001 
Screening – 
a) breast cancer,  
b) prostate cancer, 






Decisions and practice 
patterns followed HTA 
recommendations 
a) Strong influence on screening 
mammography, rapid increase after 
publication, all counties offered 
screening.  
b) HTA recommendations followed by 
the county councils, none organised 
screening programs for prostate cancer. 
Opportunistic testing thought to be 
relatively common and increasing in rate. 
c) Introduction of routine screening was 
recommended and became routine 
aajor  4 
Britton [19], 2002 
a) Preoperative 
examinations  




c) Prostate cancer 
screening. 
d.  Bone density 
measurement 
e. Neuroleptics as 
calming therapy for 
old persons  
















a) aajor decrease in pre- op exams 
b) Levelling off in increase of ACE 
inhibitor, calcium channel blocker 
prescriptions 
c)  Huge increase in PSA test use 
d) Increase in sales of BDa machines 
e) Slow decrease in use of antipsychotic 
drugs, larger in Kronoberg County which 
made a concerted effort to reduce 
f) National trend in prescriptions for PP 
inhibitors unclear, overall cost for anti- 
dyspepsia drugs 8% less. 
Decrease in PPI use in Skellefteå County 
through local drug committee initiative 




Some input to 





Supplementary Table 1 (continued) 
Author, 
Technology 
Country/setting Types of 
decision 














Practice vuestionnaire survey, 
comparison with previous 
investigation, reference to 
SBU report and a guideline 
Awareness of guideline reported by 90% 
hygienists, 66% dentists 
Information in guideline used by 54% 
hygienists, 34% dentists  
25% of dental professionals reported 
increased tobacco cessation consultation  
However , no change in number of patients 
receiving cessation support or the mean 














Analysis of medical journals 
and government reports
   
  
Noted control and regulation of serum 
screening by the political decision-makers, 
allocation of funding. A counter influence 
was promotion by the medical community, 
aajor  5 
 Fischer [22], 
2011 Newborn 
screening 
11 EU countries Coverage Association between HTAs 
and coverage decisions in EU 
countries 
7 decisions with HTA, 15 
without 
Association between HTA and coverage 
decision processes was more explicit,  





















HTA provided information on options for 
optimum screening programs, identified 
major policy questions that required public 
discussion. National committee 
subsequently opened up this discussion 
aajor   
5 
  
Supplementary Table 1 (continued) 
Author, 
Technology  
Country/setting Types of 
decision 




Carlsson [24], 2001 
a)  Cardiac bypass 
surgery 
b)  Chiropractic 







Review of administrative, 
policy developments 
a). HTA, other reports linked to 
change in policy and expansion of 
open heart surgery services 
b).  Results of RCT, including costs,  
were input to decision by politicians at 
local level (no difference in cost-
effectiveness)  
Some input to 
decisions 
a) = 2 
b)= 4 
Gagnon [25], 2006 
a. insulin pump 
b. prioritization for 
cataract surgery 
c. prioritization 










according to theoretical 
dimensions and contextual 
factors 
Adoption of HTA recommendations 
depends on a conjunction of factors 
(institutional, organizational, 
professional) that is unique to the 





Bergh [26], 2010 
a) Bariatric surgery 




















a) Use by local authorities & regions  
b) Funded and implemented  
c) Widely recommended for screening  




Some input to 





Supplementary Table 1 (continued) 
Author, 
Technology 
Country/setting Types of 
decision 




Burns [27], 2007 
clip appliers, 
staplers, trocars, 









Evaluation by surgeons of 
comparable medical devices 
in standardized surgical 
procedures, and use of 
evaluation findings by a 
hospital purchasing 
organization 
Products from 8 vendors evaluated 
and ranked for ergonomics, 
functionality, performance, clinical  
acceptability. 
 1 vendor received consistently higher 
ratings than the others across all 
product categories; 2 received 
consistently low ratings for several 
product categories. Findings were 
used by the purchasing organization 
to select the vendor(s) they wished to 
contract with 
 
aajor   
2 
BCBS [28], 2008 
Pharmacogenomics 
USA, National Coverage, 
Referral 
Review of policy response to 
assessment 
Policy statement that genotyping to 
determine cytochrome p450 
(CYP2C19) genetic polymorphisms is 
considered investigational for 
managing the treatment of H. pylori 
infection. No change in 2011 
aajor  2 






PRC, National Guideline, 
Practice 
Responses to contracted 
assessments, action by the 
ainistry of Health 
Guidelines issued by the ainistry of 
Health, based on HTA material 
aajor  2 
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Author, 
Technology 
Country/setting Types of 
decision 






























Formal decision process 
linked to HTA findings, 
review of health ministry 
decisions 
a) To be publicly funded; regions to 
determine whether they will offer 
bariatric surgery 
b) Regions to introduce service and 
determine best service delivery 
model. All adopted the service. 
Expected health system savings were 
not achieved (reliance on false-
positive test results). 
c) Not funded because of 
investigational nature 
d) Introduction of province-wide 
screening, funding provided 
e) Expansion of list from 3 to 16 
conditions, funding provided 
aajor  4 










Example from review of 
development of economic 
evaluation of health 
technologies in the UK and 
its impact on decision 
making 
NICE deemed none of the drugs to be 
cost effective at incremental cost per 
vALY of £35 000–104 000.  
Department of Health intervened with 
scheme that accepted a  
maximum threshold cost per vALY of 
£36 000.  If the patient’s progress 
failed to equate with an ICER of 
£36000 or less the cost of the drug to 
the NHS would be rebated. 
Some input to 




Supplementary Table 1 (continued) 
Author, 
Technology 
Country/setting Types of 
decision 






a. Exacerbation of 
COPD, - prognostic 
factors  









of home care in 
exacerbation 
episodes of COPD 
using a respiratory- 
function unit 
e) aanagement of 
bacterial resistance 








vualitative study of six 
projects on respiratory 
diseases funded between 
1996 and 2004. Semi-
structured interviews with 
15 researchers and 8 
healthcare decision-makers 
aost participants indicated changes in 
health services or clinical practice had 
resulted from research. 
“The barriers and facilitators identified 
were mostly organizational (in 
research management, and clinical 
and healthcare practice)…. Both the 
expected and achieved impacts 
enabled the identification of the gaps 
between what is expected and what is 
truly achieved.” 
 
No specific recommendations for 
policy makers; 
Some input to 
decisions   
3 
  
Supplementary Table 1 (continued) 
Author, 
Technology 
Country/setting Types of 
decision 




Bowen 2007 [34], 
Opinion Leader 
Research [35], 2003  
 
Draft Economic 
Development, Waste,  
Energy, London Plan 
strategies 













to evaluate 4 health 
impact assessments 
(HIAs) of draft 
mayoral strategies. 
Included group 




with public health staff 
by GLA 
Wider consultation 
during development of a 
strategy 
Strategies were revised 
as a result of outputs 
from HIAs 
Strategy team reported 
few barriers to 
incorporating 
recommendations into 












Country/setting Types of 
decision 




aad [36], 2012 






Coverage Analysis of whether HTA advice 
to regulate coverage was 
accepted by the ainistry of 
Health 
HTAs recommended coverage with 
limitations for 11 interventions and did 
not recommend for 22. ainistry 
decided on acceptance in 7 cases, 
rejection in 18 and changed the status 
to ‘subject to approval’ in 7 
 














Analysis of administrative data 
from hospitals and  
health insurance funds. 
Interviews with representatives 
of administrations and payers 
Findings from 9 of 11 full HTAs 
contributed to decisions by insurance 
funds and hospital management. 
Recommendations from 19 of 42 rapid 
assessments accepted by hospital 
financing board. 
Findings from 6 of 7 HTAs contributed 
to disinvestment decisions which led to 




















Review of impact of reports 
published during 2009-2011.  
Information from project staff, 
other contacts, websites, 
legislation. 
Direct impact if at least one 
recommendation was 
implemented;  indirect impact if 
recommendations featured in 
debate but were not yet 
implemented 
11 reports with recommendations 
aimed at health care professionals 
classified as “not measured” 
About half of the remaining 67 reports 
had a direct impact and about one third 
were currently under discussion 
In the case of one HTA report a decision 
was taken that went directly against 
recommendations 
aajor  5 
  
 
Supplementary Table 2 (continued) 
Author,  
reports 
Country/setting Types of 
decision 







public health care 
system 
Coverage Consideration of policy 
decisions based upon CED 
studies. Compared decisions 
with results of studies 
In  9 cases decisions were 
consistent with HTA 
recommendations, awaiting 
results for the other HTA 
 















a) vualitative research -
interviews with HTA program 
clients 
b) Data collected by HTA 
program using form in part 
based on INAHTA instrument.  
a) Eight of 10 products 
informed policy and resource 
allocation decisions.  
b) Feedback from clients, 
decisions on HTA 
recommendations, inclusion of 
HTA material in documentation 
a)Some input to 
decisions    
b) 3 HTAs, had major 
influence, 16 input 
to decisions, 3 some 
consideration, 3 








Health Centre (five 
teaching hospitals)  
within  the vuébec 
healthcare system. 
Local in-hospital 







Evaluation of the extent to 
which reports have influenced 
hospital policy decision making 
and spending. Feedback from 
individuals responsible for 
technologies in question 
 
Of 63 policy recommendations, 
45 were accepted and 
incorporated into Health Centre 
policy. 1 was partially 
incorporated, 17 were not 
incorporated into policy. 
 
 
aajor influence on 
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Canada, Department of 
Surgery & Surgical 






Retrospective analysis on 
outcomes of a local HTA 
program over 5 years 
Local HTA committee 
decisions categorised 
12 applications approved, 3 approved 
for a single case on an urgent basis, 21 
approved for a restricted number of 
cases with outcomes review, 14 for 
research use only, 3 referred to 











France, Hospital network, 





a) vualitative – semi 
structured interviews with 
persons affected by HTA 
recommendations 
b) Review of decisions 
following 13 HTAs 
 7 aajor influence, usually through 
funding being approved or withheld 
 3 difficult to distinguish between HTA 
influence and that of experience gained 
during supplementary studies 
 1 ainimal influence , decision contrary 
to recommendation 













Germany, National – 
committee responsible 
for ambulatory health 




Considered whether HTA 
recommendations were 
accepted by the 
committee 
The committee decisions were 
consistent with HTA recommendations 
 
aajor   2 
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Author,  
reports 













for head injury, 











Survey of persons in 
public hospitals, health 
departments, research 
institutes and ainistry 
of Health. 
% participant responses:  
Recommendations/ conclusions 
accepted : 83% 
Showed  technology met program 
requirements: 79% 
aaterial incorporated into policy 
documents: 69% 
Used as reference material: 78% 







Ju [48 ], 2014 
 








Review of HTA decisions 
and their 
implementation 
19 HTAs recommended funding for 
piloting of the technologies; this had 
commenced for 17 with final decision 
pending for 2. (e.g. greenlight laser 
therapy, electromagnetic navigation 
bronchoscopy, Xpert aTB/RIF, 
excimer laser system) 
Funding not recommended for 7 
technologies (e.g. percutaneous 
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reviewed to assess to 
what extent policy-
makers had used the 
information coming 
from the HTAs 
34 drugs appraised and reimbursed 
(4 negative and 30 positive HTA 
recommendations) 
117 appraised and not reimbursed 









Large numbers of 
drugs 
France, National Coverage 
  
Review of ainistry & 
sickness fund decisions 
following HTA 
recommendations 
> 95 % of positive HTA opinions on 
reimbursement status of a new 
technology were followed by 
decisions to reimburse. Almost all 
negative opinions were followed. 
1999 – 2001: concluded 835 of 4,490 
medicines showed insufficient 
benefit, reimbursement rates were 
reduced 
2003 – 06: proposed delisting 370, 
322 were delisted, decision to retain 
48 drugs for cerebral insufficiency in 
the elderly population. 
aajor  3 
Teerawattananon  
[51 ], 2014 
Thailand, 
National – public 
health insurance 
program 
Coverage Review of decisions by 
Subcommittee for 
development of the 
National List of Essential 
aedicines on 
recommendations for 
inclusion of medicines 
in the list, based on 
economic and other 
assessments. 
Ten medicines were accepted for 
inclusion in the national list, 11 were 
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Author,  
reports 














d for use 
Scotland – National 
Health Service 
Practice Analysis of effect of 
advice from the SaS on 
use of medicines.  
Volume of prescribing  
measured by each 
medicine’s gross 
ingredient cost to the 
prescribing budget 
Data were available for 8 of 10 
medicines not recommended for use. 
Use increased for 5 medicines, 
stabilized for 2 and decreased for 1. 
(Data show that use of one medicine 


















UK - ambulatory care 
of the NHS in England 
and Wales 
Practice Secondary analysis 
from the prescription 
costs analysis statistics 
and comparison with 
NICE recommendations 
For 97 % of the drugs, the publication 
of NICE's 14 negative and restricting 
technology appraisals between 2000 
and 2004, did not reduce the number 
of prescription items dispensed or 
net ingredient costs in the 





20 rapid HTAs 






Interviews and written 
feedback with 
requestors of HTA or 
persons who might be 
influenced by the 
findings 
Decisions by health ministry 
consistent with HTA advice.  Two 
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Canada, Spain, USA – 












Survey of INAHTA 
members on rapid 
HTAs that they had 
prepared during 2006. 
All the HTAs were considered to have 
had some influence. aost common 
indications were consideration by the 
decision maker, use of the HTA as 
reference material (both n = 10), and 
acceptance of recommendations or 





























supported by the 
Dutch HTA program 
Program, 
Practice 
Case studies using 
“payback framework”.  
Authors comment that “it is too early 
to fully assess impact of the Dutch 
HTA program” 
Details might provide a baseline for 
future appraisal of payback 
Two examples of changes in practice  
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Review of first 10 years of NHS HTA 
Programme, included 
questionnaire survey of lead 
investigators and 16 case studies. 
Analysis using payback framework 
Concluded programme had 
perceived impact on policy and 
to some extent on practice. 73% 
of survey respondents claimed 
projects had impacted on policy 
and 56% on behaviour (96% for 
TARs) 
11 of 16 case studies thought to 











funded by an 
HTA programme 






Review of NHIS HTA Programme 
from 2003-2013. Interviews with 
20 senior stakeholders 
Electronic survey of HTA grant 
holders.  
12 payback case studies  
of HTA programme-funded 
research. 
*Interviews indicated the 
primary route to impact of 
programme-funded research on 
patients is through influence on 
guidelines.  
* Survey responses for 93 HTA 
program projects reported an 
impact on policy, including 
citation in guidelines and other 
documents. 
* 7 out of 12 case studies  
provided some evidence  
research had an impact on the 
NHS and patients, and 4 
included limited evidence of 
changes in clinical practice. 
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Turner [59 ], 
2015 
 
122 NICE clinical 
guidelines, 
issued between 
April 2001 and  
April 2012 
UK – NHS England & 
Wales 
Guideline Retrospective cohort study, 
proportion of NICE guidelines 
which cited evidence from studies 
funded by the NIHR HTA 
Programme and the impact of 
those studies on the guidelines  
Of 122 guidelines, 3 (2%) were 
based on previous NIHR HTA 
reports and 90 (74%) cited 
evidence from NIHR HTA studies. 
The impact of HTA evidence on 
the guidelines varied; the ways in 
which data was used by NICE was 
heterogeneous. There was 
extensive use of NIHR-HTA data 
in guidelines on Chest Pain of 
Recent Onset, The Epilepsies and 




Rosén [60], 2014 
 












aeasured the extent to which HTA 
reports had affected decisions, 
guidelines, research or clinical 
practice. Used documentation, 
before-after surveys and time 
series register data.  
Decisions and actions of national 
and local government bodies, 
and of professional 
organizations. Changes in use of 
technologies and services.  
HTA reports had a high impact 
on clinical guidelines, and a 
moderate or high impact on 
comprehensive decisions, 
initiation of research and 
changes in clinical practice. 
Impact was low in three cases.  
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HTAs from other 
jurisdictions 











Survey of decision makers and 
researchers on HTA 
transferability experiences 
Decision makers reported 
using HTAs from other 
jurisdictions to guide 
decisions in the majority of 
cases:  
52.6 % HTAs from outside LAC 
23.1 % from other LAC 
countries,  
24.3 %HTAs from their own 
countries.  
63 % of researchers reported 
using HTAs from other 
jurisdictions; information 
regarding safety and 
effectiveness was considered 
more applicable than that on 
social aspects, or economic 
evaluation 
Some  
consideration  
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